These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9858385)

  • 1. Effects of YM872 on atrophy of substantia nigra reticulata after focal ischemia in rats.
    Ni JW; Takahashi M; Yatsugi S; Shimizu-Sasamata M; Yamaguchi T
    Neuroreport; 1998 Nov; 9(16):3719-24. PubMed ID: 9858385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats.
    Kawasaki-Yatsugi S; Yatsugi S; Takahashi M; Toya T; Ichiki C; Shimizu-Sasamata M; Yamaguchi T; Minematsu K
    Brain Res; 1998 May; 793(1-2):39-46. PubMed ID: 9630503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion.
    Håberg A; Takahashi M; Yamaguchi T; Hjelstuen M; Haraldseth O
    Brain Res; 1998 Nov; 811(1-2):63-70. PubMed ID: 9804894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YM872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist.
    Takahashi M; Kohara A; Shishikura J; Kawasaki-Yatsugi S; Ni JW; Yatsugi S; Sakamoto S; Okada M; Shimizu-Sasamata M; Yamaguchi T
    CNS Drug Rev; 2002; 8(4):337-52. PubMed ID: 12481190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YM90K, an AMPA receptor antagonist, protects against ischemic damage caused by permanent and transient middle cerebral artery occlusion in rats.
    Kawasaki-Yatsugi S; Ichiki C; Yatsugi S; Shimizu-Sasamata M; Yamaguchi T
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):586-91. PubMed ID: 9840429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiological studies of rat substantia nigra neurons in an in vitro slice preparation after middle cerebral artery occlusion.
    Nakanishi H; Tamura A; Kawai K; Yamamoto K
    Neuroscience; 1997 Apr; 77(4):1021-8. PubMed ID: 9130783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats.
    Shimizu-Sasamata M; Kano T; Rogowska J; Wolf GL; Moskowitz MA; Lo EH
    Stroke; 1998 Oct; 29(10):2141-8. PubMed ID: 9756596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats.
    Takahashi M; Ni JW; Kawasaki-Yatsugi S; Toya T; Ichiki C; Yatsugi SI; Koshiya K; Shimizu-Sasamata M; Yamaguchi T
    J Pharmacol Exp Ther; 1998 Nov; 287(2):559-66. PubMed ID: 9808681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YM872, a novel selective alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats.
    Takahashi M; Ni JW; Kawasaki-Yatsugi S; Toya T; Yatsugi SI; Shimizu-Sasamata M; Koshiya K; Shishikura JI; Sakamoto S; Yamaguchi T
    J Pharmacol Exp Ther; 1998 Feb; 284(2):467-73. PubMed ID: 9454786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model.
    Kawasaki-Yatsugi S; Ichiki C; Yatsugi S; Takahashi M; Shimizu-Sasamata M; Yamaguchi T; Minematsu K
    Neuropharmacology; 2000 Jan; 39(2):211-7. PubMed ID: 10670416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of N-methyl-D-aspartate receptor in the delayed transneuronal regression of substantia nigra neurons in rats.
    Yamada K; Goto S; Yoshikawa M; Okamura A; Ushio Y
    Brain Res; 1996 Dec; 743(1-2):233-9. PubMed ID: 9017250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effect of a novel AMPA receptor antagonist, YM90K, in rat focal cerebral ischaemia.
    Umemura K; Shimakura A; Nakashima M
    Brain Res; 1997 Oct; 773(1-2):61-5. PubMed ID: 9409705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPA receptor antagonist, YM90K, reduces infarct volume in thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats.
    Yao H; Ibayashi S; Nakane H; Cai H; Uchimura H; Fujishima M
    Brain Res; 1997 Apr; 753(1):80-5. PubMed ID: 9125434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist.
    Kohara A; Okada M; Tsutsumi R; Ohno K; Takahashi M; Shimizu-Sasamata M; Shishikura J; Inami H; Sakamoto S; Yamaguchi T
    J Pharm Pharmacol; 1998 Jul; 50(7):795-801. PubMed ID: 9720630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of a novel AMPA receptor antagonist, YM872.
    Small DL; Murray CL; Monette R; Kawasaki-Yatsugi S; Morley P
    Neuroreport; 1998 May; 9(7):1287-90. PubMed ID: 9631414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model.
    Terai K; Suzuki M; Sasamata M; Yatsugi Si; Yamaguchi T; Miyata K
    Eur J Pharmacol; 2003 Apr; 467(1-3):95-101. PubMed ID: 12706461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ability of NMDA and non-NMDA receptor antagonists to inhibit cerebral ischemic damage in aged rats.
    Suzuki Y; Takagi Y; Nakamura R; Hashimoto K; Umemura K
    Brain Res; 2003 Feb; 964(1):116-20. PubMed ID: 12573519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats.
    Kawasaki-Yatsugi S; Shimizu-Sasamata M; Yatsugi S; Yamaguchi T
    J Pharm Pharmacol; 1998 Aug; 50(8):891-8. PubMed ID: 9751454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraarterial urokinase produces significant attenuation of infarction volume in an embolic focal ischemia model.
    Shuaib A; Yang Y; Li Q; Siddiqui MM; Kalra J
    Exp Neurol; 1998 Dec; 154(2):330-5. PubMed ID: 9878171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia.
    Matucz E; Móricz K; Gigler G; Simó A; Barkóczy J; Lévay G; Hársing LG; Szénási G
    Brain Res; 2004 Sep; 1019(1-2):210-6. PubMed ID: 15306255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.